The TEA 2/16 monoclonal antibody specifically recognizes CD109 which is also known as C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7 (CPAMD7), Gov platelet alloantigens, or 150 kDa TGF-beta-1-binding protein. CD109 is a 150-170 kDa glycosylphosphatidylinositol (GPI)-linked glycoprotein expressed on activated T cells, myeloid progenitor (CD34+) and mature myeloid lineage cells (monocytes, granulocytes, platelets), but not on CD34+ lymphoid progenitor cells. CD109 is also expressed on vein and artery endothelial cells. The expression of CD109 is upregulated on PHA-stimulated T cells. CD109 is reportedly expressed on long-term adult bone marrow cultured cells, where it is co-expressed with CD34 and CD90. Its biological role in hematopoiesis has not been fully elucidated. It may play a role in the negative regulation of transforming growth factor beta receptor signaling.
The antibody was conjugated to BD Horizon™ BUV496 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 496-nm. BD Horizon BUV496 can be excited by the ultraviolet laser (355 nm) and detected with a 515/30 nm filter with a 450LP. Due to the excitation of the acceptor dye by other laser lines, there may be significant spillover into the channel detecting BD Horizon V500 or BV510 (eg, 525/40-nm filter). However, the spillover can be corrected through compensation as with any other dye combination.